RESUMEN
Aim: To examine whether or not non-secretion of ABH substances and non-tasting of PTC are risk factors exhibiting positive interactions for tuberculosis. Methodology: A total of 210 individuals comprising 110 tuberculosis patients (test group) and 100 apparently healthy subjects (control group) participated in this study. Secretors and non-secretors were determined among the study participants by haemagglutination inhibition test and Tasters and non-tasters were determined using phenylthiocarbamide (PTC) taste strips (0.0143 mg/strip). Results: Of the 110 tuberculosis patients, 65 (59.1%) and 45 (40.9%) were secretors and non-secretors respectively while 49 (44.5%) were tasters and 61 (55.5%) were non-tasters. Of the 100 control subjects, 78% and 22% were secretors and non-secretors respectively while 67% and 33% were tasters and non-tasters respectively. Non-secretors of ABH substances were significantly more associated with test patients than controls (χ2 = 8.62, df = 1, p = 0.002). Non-tasters of PTC were significantly more associated with test patients than controls (χ2=10.68, df=1, p=0.001). When combined, secretors and tasters were significantly lower in the test group than in the control group (χ2=13.44, df=1, p<0.001) while non-secretors and non-tasters were significantly higher in the test group than in the control group (χ2=9.77, df=1, p=0.002). Individuals who were both non-secretors and non-tasters were significantly associated with tuberculosis compared to those who were not (OR 3.5; 95% C.I 1.59-7.51). Conclusion: This study shows that there is a remarkable increased incidence of tuberculosis in individuals who are both unable to secrete ABH substances and taste PTC.
RESUMEN
Chloroquine (CQ) resistance in Plasmodium falciparum contributes to increasing malaria-attributable morbidity and mortality in Sub-Saharan Africa. Despite a change in drug policy, continued prescription of CQ did not abate. Therefore the therapeutic efficacy of CQ in uncomplicated falciparum malaria patients was assessed in a standard 28-day protocol in 116 children aged between six and 120 months in Osogbo, Southwest Nigeria. Parasitological and clinical assessments of response to treatment showed that 72 (62.1 percent) of the patients were cured and 44 (37.9 percent) failed the CQ treatment. High initial parasite density and young age were independent predictors for early treatment failure. Out of the 44 patients that failed CQ, 24 received amodiaquine + sulphadoxine/pyrimethamine (AQ+SP) and 20 received chlorpheniramine + chloroquine (CH+CQ) combinations. Mean fever clearance time in those treated with AQ+SP was not significantly different from those treated with CH+CQ (p = 0.05). There was no significant difference in the mean parasite density of the two groups. The cure rate for AQ+SP group was 92 percent while those of CH+CQ was 85 percent. There was a significant difference in parasite clearance time (p = 0.01) between the two groups. The 38 percent treatment failure for CQ reported in this study is higher than the 10 percent recommended by World Health Organization in other to effect change in antimalarial treatment policy. Hence we conclude that CQ can no more be solely relied upon for the treatment of falciparum malaria in Osogbo, Nigeria. AQ+SP and CH+CQ are effective in the treatment of acute uncomplicated malaria and may be considered as useful alternative drugs in the absence of artemisinin-based combination therapies.